Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Wave Life Sciences USA, Inc.

Wave Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences Third Quarter 2024 Financial Results Scheduled for November 12, 2024
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences Highlights Growing Pipeline at Research Day, including INHBE siRNA Program for Obesity and New RNA Editing Programs
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences Announces First-Ever Therapeutic RNA Editing in Humans Achieved in RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences Announces Upcoming Virtual Research Day on Wednesday, October 30, 2024
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences Announces Closing of Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences to Present at Chardan 8th Annual Genetic Medicines Conference
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences Prices Upsized $200 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences Receives FDA Rare Pediatric Disease Designation for WVE-N531 for the Treatment of Duchenne Muscular Dystrophy
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences Second Quarter 2024 Financial Results Scheduled for August 8, 2024
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences Announces Positive Results from Phase 1b/2a SELECT-HD Trial with First Clinical Demonstration of Allele-Selective Mutant Huntingtin Lowering in Huntington’s Disease
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences Announces Upcoming Presentations Highlighting Novel siRNA Program in Obesity and Leadership in RNA Editing
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences to Present at 2024 Jefferies Global Healthcare Conference
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences to Present at 2024 RBC Capital Markets Global Healthcare Conference
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences First Quarter 2024 Financial Results Scheduled for May 9, 2024
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency (AATD)
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences to Present at Upcoming Investor Conferences
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Scheduled for March 6, 2024
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences Announces Upcoming Presentations at MDA Conference that Highlight Best-in-Class Potential for WVE-N531 in Duchenne Muscular Dystrophy
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences Highlights Recent Achievements and Upcoming 2024 Milestones
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences to Present at 42nd Annual J.P. Morgan Healthcare Conference
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences Prices $100 Million Public Offering of Ordinary Shares
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.